Related Experiment Videos

Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting

M N Hosono1, M Hosono, A K Mishra

  • 1Department of Radiology, Osaka City University, Japan.

Annals of Nuclear Medicine
|August 2, 2000
PubMed

Insights

This study shows that rhenium-188-labeled monoclonal antibodies (MAbs) modified with 2-iminothiolane (2IT) effectively target small-cell lung cancer (SCLC) in mice. These radiolabeled MAbs offer promising potential for SCLC imaging and therapy.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Immunotherapy

Background:

  • Small-cell lung cancer (SCLC) remains a challenging malignancy with limited targeted treatment options.
  • Monoclonal antibodies (MAbs) offer specific targeting capabilities for cancer therapy.
  • Rhenium-188 (188Re) is a promising radioisotope for targeted radionuclide therapy due to its decay properties.

Purpose of the Study:

  • To evaluate the efficacy of 188Re-labeled monoclonal antibodies (MAbs) modified with 2-iminothiolane (2IT) for targeting small-cell lung cancer (SCLC).
  • To compare the tumor-targeting potential of two specific MAbs, NK1NBL1 and C218, against SCLC.
  • To assess the biodistribution and pharmacokinetic profile of these radiolabeled MAbs in a preclinical model.

Main Methods:

  • Development and radiolabeling of MAbs NK1NBL1 and C218 with 188Re using 2IT conjugation.
  • Intravenous administration of radiolabeled MAbs into athymic mice bearing human SCLC xenografts.
  • Biodistribution studies to quantify MAb uptake in tumors, blood, and other organs.
  • Comparison of 188Re-labeled MAbs with their 125I-labeled counterparts.

Main Results:

  • Both 188Re-labeled MAbs, NK1NBL1 and C218, demonstrated localization in SCLC tumors.
  • MAb NK1NBL1 exhibited superior tumor localization compared to MAb C218.
  • 188Re-labeled MAbs showed faster clearance from the bloodstream than 125I-labeled MAbs.
  • Significantly higher tumor-to-blood ratios were achieved with the 188Re-labeled MAbs.

Conclusions:

  • 188Re-labeled MAbs, particularly NK1NBL1, modified with 2IT are effective agents for targeting SCLC.
  • The rapid blood clearance of 188Re-labeled MAbs enhances tumor visualization and therapeutic potential.
  • These findings support the further development of 188Re-labeled MAbs for clinical applications in SCLC imaging and therapy.

Related Concept Videos